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Classical Li-Fraumeni syndrome (LFS) families have a proband
with sarcoma under the age of 45 years, a first-degree relative with
any cancer under age 45, and a first-or second-degree relative with
either a sarcoma at any age or any other cancer under age 45 years
(Li and Fraumeni, 1969; Li et al, 1988). Li-Fraumeni-like (LFL)
families conform to a broader definition (Birch et al, 1994) with a
proband having any childhood cancer or sarcoma, brain tumour or
adrenal cortical tumour diagnosed before age 45 years with one
first- or second-degree relative with a typical syndromal cancer at
any age, plus a first- or second-degree relative with any cancer
under age 60 years. In both syndromes the predominant cancers
are bone and soft tissue sarcomas and breast cancer, plus an excess
of brain tumours, leukaemia and adrenocortical carcinomas diag-
nosed under age 45 years. We have reported germline mutations in
the tumour suppressor gene, TP53, in 14 of 21 LFS families and
four of 18 LFL families (Birch et al, 1994; Varley et al, 1997). An
understanding of the consequences of the p53 mutations, particu-
larly in the mesenchymal cells, could have implications for the
management and counselling of these families.
Pioneering work by Little (1968, 1970) demonstrated that human
cells arrest in the G1 phase of the cell cycle following exposure 
to ionizing radiation. Subsequently, it was shown that radiation-
sensitive fibroblasts from patients with the cancer predisposition
syndrome, ataxia-telangiectasia (AT), did not show this response
(Little and Nagasawa 1985; Nagasawa et al, 1985). These observa-
tions can be explained by the fact that radiation-induced stabiliza-
tion of p53 expression in AT cells is both delayed and is reduced
compared to normal cells, resulting in lower levels of transactiva-
tion of the cyclin-dependent protein kinase inhibitor, p21WAF1/CIP1,
which has been strongly implicated in the permanent arrest of cells
in G1 (Di Leonardo et al, 1994; Dulic et al, 1994).
Recently, we reported that radiation-resistant fibroblasts from
Li-Fraumeni (LF) individuals also show reduced G1 arrest
(Williams et al, 1997). We now report an enlarged study of G1
arrest in which we have compared the variability in responses of
12 fibroblast strains from normal volunteers with that of 30 strains
from 20 classic LFS or LFL families. We have used this material to
answer the following questions:
1. Permanent G1 arrest has been reported following irradiation
of cells synchronized in G1 (Little, 1968, 1970) and transient
arrest has been reported following irradiation of
asynchronous cells (Kastan et al, 1991). Li et al (1995)
questioned whether the two conditions gave the same
measure of G1 arrest, but did not answer the question directly.
We have directly compared the two methods using the
enlarged panel of cells.
2. Do different TP53 mutations produce different G1 arrest
responses?
3. How does loss of the wild-type (wt) allele affect the response?
4. What is the response in cells from LF families in which no
TP53 mutation has been found despite exhaustive sequencing
of all exons, exon–intron boundaries, 3¢ and 5¢ untranslated
regions and the promoter region (Varley et al, 1997)?
5. To what extent is reduced G1 arrest a predictor of clonogenic
radioresistance?
Radiation-induced G1 arrest is not defective in
fibroblasts from Li-Fraumeni families without TP53
mutations
JM Boyle1, MJ Greaves1, RS Camplejohn2, JM Birch3, SA Roberts4 and JM Varley1
CRC Sections of 1Molecular Genetics and 4Biomathematics and Computing, Paterson Institute for Cancer Research, Christie CRC Research Centre,
Manchester M20 4BX, UK; 2Richard Dimbleby Department of Cancer Research, UMDS, St. Thomas’s Hospital, London SE1 7EH, UK; 3CRC Paediatric and
Familial Cancer Research Group, Royal Manchester Children’s Hospital, Manchester M27 4HA, UK
Summary Radiation-induced G1 arrest was studied in four classes of early passage skin fibroblasts comprising 12 normals, 12 heterozygous
(mut/wt) TP53 mutation-carriers, two homozygous (mut/–) TP53 mutation-carriers and 16 strains from nine Li-Fraumeni syndrome or Li-
Fraumeni-like families in which no TP53 mutation has been found, despite sequencing of all exons, exon–intron boundaries, 3¢ and 5¢
untranslated regions and promoter regions. In an assay of p53 allelic expression in yeast, cDNAs from these non-mutation strains behaved
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truncation mutation, when compared to the range established for the normal cells. Heterozygous strains with mutations at splice sites
behaved like normal cells, whilst homozygous (mut/–) strains showed either extremely reduced, or no, arrest. Strains from all nine non-
mutation families gave responses within the normal range. Exceptions to the previously reported inverse correlation between G1 arrest and
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Fibroblast strains and clonogenic survival
Most fibroblast strains used here and their culture conditions have
been described in detail (Boyle et al, 1998; Varley et al, 1998). The
origins of additional strains are given in Table 1. Early passage
cultures were used in the experiments reported. Clonogenic survival
following exposure to low-dose rate (0.011 Gy per min) 60Co radia-
tion was measured as previously described (Boyle et al, 1998).
Measurement of G1 arrest
Radiation-induced G1 arrest was determined by two methods.
Transient arrest was determined essentially as described by Kuerbitz
et al (1992). Confluent cultures were subcultured by 1:3 dilution
approximately 3 days before trypsinization. Asynchronous cell
suspensions at 1 ´ 106 per ml were irradiated at room temperature
with 0, 0.5 or 4 Gy 137Cs gamma radiation at a dose rate of 3.3 Gy
per min, then 1 ml aliquots were inoculated into T150 flasks
(Falcon) and incubated at 37°C for 17 h. BrdU was added to 10 mM
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Table 1 Donor details, allelic expression and the magnitude of radiation-induced G1 arrest in fibroblast cultures
Strains aFamily Type Mutation Age at Sex bFASAY dTransient arrest ePermanent arrest
(person) biopsy
cn 0.5 Gy 4 Gy cn 4 Gy
Group 1 – Normal controls
83MA 34 F 1 62.6 90.9 2 85.1 ± 4.0
85MA 28 M 4 (wt/wt) 1 66.6 92.5 2 50.2 ± 0.8
93MA 19 M 4 (wt/wt) 1 61.5 89.7 1 67.4
105MA 58 M 1 67.8 95.7 1 74.1
120MA 47 F 1 50.0 86.4 2 74.7 ± 7.4
136MA 83 (I-1) fPrior to 77 M 1 54.2 81.4 1 62.1
141MA 83 (I-2) mutation 77 F 1 – 85.7 1 76.6
156MA 35 F 6 57.1 ± 3.9 91.0 ± 6.0 1 66.1
162MA 27 F 1 53.8 90.3 1 69.5
176MA 31 F 8 55.4 ± 10.3 94.3 ± 1.8 2 71.8 ± 1.9
177MA 2635 (III-1) gSpouse 68 M 4;4 (wt/wt) 1 72.6 97.1 2 80.3 ± 2.8
187MA 86 gSpouse 42 M 1 59.4 93.0 1 90.9
Group 2 – Mutation-carrier families (mut/wt strains)
FH1 266 (II-4) LFS aff R248W/wt 20 M 1 12.5 54.6 3 29.2 ± 7.1
163MA 266 (II-2) LFS aff R248W/wt 31 F 1 10.2 59.3 1 27.5
131MA 222 (IV-1) LFS aff R248Q/wt 18 M 1 24.5 25.5 1 25.2
138MA 83 (III-4) LFS unaff R175H/wt 16 M 45 (mut/wt) 1 28.1 73.5 1 39.2
124MA 16 (IV-1) LFS aff Y220C/wt 13 F 65 (mut/wt) 1 12.5 45.8 3 14.9 ± 7.0
109MA 85 (III-7) LFL unaff E180K/wt 52 M 49 (mut/wt) 1 35.6 84.2 2 57.1 ± 4.6
110MA 85 (IV-1) LFL aff E180K/wt 18 F 58 (mut/wt) 2 43.0 ± 1.6 84.7 ± 5.2 3 51.3 ± 10.7
168MA 1502 (III-1) LFL aff R273H/wt 31 F 1 28.7 69.1 –
178MA 2635 (IV-8) LFL aff spl.donor 39 F 3 (wt/wt) 1 67.5 93.5 4 63.5 ± 10.7
exon 4/wt
191MA 86 (V-5) LFS aff spl. acc. 16 M 1 52.1 88.2 –
intron 3/wt
193MA 2612 (III-1) LFS aff R209stop/wt 41 M 12,12 (wt/wt) 1 43.8 75.2 1 44.8
194MA 64 (III-5) LFS unaff P152L/wt 42 F 57,56 (mut/wt) 1 3.0 59.8 1 54.6
Group 3 – Mutation-carrier families (mut/–strains)
161MA-F 7379 (III-6) LFS aff L344P/- 45 M 97 (mut/–) 1 –7.1 ± 12.8 –3.7 ± 7.8 1 14.1
172MA i LFS aff R337C/- 34 F 1 –17.7 –1.9 1 19.5
Group 4 – Non-mutation carriers
140MA 22 (III-4) LFS aff 14 F 5 (wt/wt) 1 60.5 72.2 3 78.6 ± 11.3
146MA 80 (IV-19) LFL aff 65 F 4 (wt/wt) 1 47.8 61.2 1 67.3
147MA 80 (V-4) LFL aff 42 F 4 (wt/wt) 1 76.1 92.5 4 72.8 ± 10.1
148MA 80 (V-5) LFL unaff 38 M 1 62.4 94.1 1 88.4
154MA 80 (V-6) LFL aff 36 F 1 62.0 96.1 1 56.1
79MA 81 (III-5) LFS aff 70 F 9 (wt/wt) 1 70.0 96.5 2 72.5 ± 0.5
80MA 81 (IV-1) LFS aff 45 M 12;9;4 (wt/wt) 1 64.6 94.6 1 58.7
81MA 81 (IV-3) LFS unaff 40 F 9 (wt/wt) 1 47.6 90.6 3 56.4 ± 2.1
115MA 82 (IV-5) LFS aff 21 M – – – 1 70.0
126MA 88 (II-2) LFS aff 29 M 5 (wt/wt) 2 69.1 ± 9.8 93.8 ± 0.4 2 74.4 ± 0.5
130MA 88 (I-1) LFS unaff 59 M 1 28.0 71.0 2 85.1 ± 8.0
121MA 119 (II-2) LFS aff 43 M 8 (wt/wt) 1 45.6 75.0 1 75.2
122MA 119 (II-1) LFS aff 46 M 1 47.4 76.3 1 73.2
127MA 338 (III-2) LFL aff 38 F 7;7 (wt/wt) 1 58.8 92.6 2 78.9 ± 4.9
128MA 348 (III-2) LFL unaff 43 F 26;15;8(wt/wt) 1 65.5 95.7 1 79.4
107MA 353 (III-3) LFL aff 34 F 6 (wt/wt) 1 45.2 90.3 1 77.5
aFamily and person numbers as listed in Varley et al (1997); b% red (mutant) colonies obtained from separate cDNA preparations with the inferred allelic
expression in parentheses; cn, number of determinations; dValues are % inhibition of S phase; eValues are % reduction of labelled cells; fParents of de novo
mutation; gUninvolved spouse; hCancer affected (aff) or unaffected (unaff) at time of biopsy; iBarnes et al (1992). M, male; F, female.and incubation was continued for 4 h, when the cells were harvested
by trypsinization, washed in phosphate buffered saline (PBS), resus-
pended and fixed in 70% ethanol. Fixed suspensions were stored at
–20°C prior to staining for FACS analysis. Suspensions were treated
at room temperature with 2 N hydrochloric acid for 30 min, then
neutralized with borate buffer. Cells were stained by sequential
adsorption of mouse anti-BrdU monoclonal antibody, clone BU20a,
and rabbit anti-mouse antibody conjugated to fluorescein isothio-
cyanate (FITC; both from Dako A/S, Denmark). Incorporation of
BrdU was analysed by FACS on a FACSCAN using Cellquest
(Becton-Dickinson) software.
Permanent G1 arrest was determined according to Williams et al
(1997). Monolayer cultures were held confluent for 10–14 days
prior to 48 h incubation in medium containing 0.1% fetal calf
serum. The G1 synchronized monolayers were irradiated with 0 or
4 Gy  137Cs gamma radiation (3.3 Gy per min), trypsinized and
plated at 4 ´ 104 cells per 3 cm diameter petri dish with 1 mCi [3H]-
TdR (20 Ci per mM; New England Nuclear). Five plates at each
dose were fixed at intervals between 60 and 120 h post-irradiation
incubation, the period corresponding to the maximum cumulative
labelling index. Plates were coated with Ilford K5 photographic
emulsion and stored at 4°C for about 2 weeks prior to developing
and staining with Giemsa. The mean fraction of cells with labelled
nuclei was determined for each set of five plates and the
percentage of inhibition of S phase was calculated by comparing
the labelled fractions of the irradiated and unirradiated cells.
Functional assay of alleles in yeast (FASAY)
Messenger RNA was extracted from early passage cells and cDNA
was derived and used to test the ability of p53 to transactivate a
target gene as previously described (Flaman et al, 1995; Lomax et
al, 1997).
Statistical analysis
Statistical analysis was performed using the SPSS statistics
package. Fibroblast strains were grouped as normal, LF with muta-
tion and LF without mutation, according to their origin and TP53
status. G1 arrest was analysed using the Mann–Whitney U-test to
G1 arrest in Li-Fraumeni family fibroblasts 1659
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Figure 1 FACS profiles of BrdU labelled cells. Cells were irradiated as indicated and labelled with BrdU under conditions of transient arrest (Materials and
methods). Panels show the bivariate distributions and gating of unlabelled G1 and G2 cells and the cells that were in S phase at the time of labelling. Values
show the percentage inhibition of S phase in a normal control (83MA) and an LFS strain (FH1)compare the group means of the aggregated data of all assays.
Transient and permanent arrest data were compared using
Spearman’s rank correlation.
RESULTS
Experiments were performed on four groups of cells represented
by 12 strains derived from normal individuals, 12 TP53 heterozy-
gous strains from LFS and LFL families, two strains with TP53
mutations that had lost the wild-type allele and 16 strains derived
from nine non-mutation families (Table 1).
Allelic expression in yeast
As an additional test for the absence of TP53 mutations in cells
derived from families in which no mutations had been detected by
sequencing, fibroblast-derived cDNA was used to test the ability
of p53 to transactivate a target gene in yeast cells. Fibroblasts from
classic LFS families having mis-sense mutations in the DNA
binding region of p53 were used as positive controls (e.g. codons
180, 220) and resulted in an approximately 1:1 ratio of mutant:wt
colonies (49–65% mutant; Table 1). Strain 161MA-F, which
showed loss of the wild-type allele (mut/–) gave virtually 100%
red (mutant) colonies. Cells from normal individuals acted as
negative controls and yielded a background frequency of red
colonies of < 10%. A mutation affecting splicing (178MA), and a
mutation in codon 209 converting it to a stop codon (193MA),
were not detected as mutant in the transactivation assay. We used
the assay to test p53 expression in fibroblasts from each of the nine
LF families in which no TP53 mutations had been found. In no
case was a 1:1 ratio of colonies observed and seven families gave
< 10% red colonies indicative of wt p53. However, cells from two
families, represented by 80MA and 128MA, consistently gave
somewhat elevated frequencies of red colonies, but not
approaching a 1:1 ratio. Also, when compared with our experience
of normal cells or mis-sense LFS, there was greater variability in
the range of values obtained with different cDNA preparations of
these cases.
G1 checkpoint
The effect of mutations in the p53 gene on the G1 checkpoint was
determined by comparing the proportion of cells in S phase
following 137Cs radiation. Two independent sets of data were
acquired: transient arrest in asynchronous cells was determined by
FACS analysis of BrdU incorporation, permanent arrest in cells
synchronized in G1 at the time of irradiation was determined by
autoradiography of [3H]TdR uptake.
Transient arrest
Figure 1 shows examples of the DNA profiles and gating of the
FACS analyses of a normal control (83MA), and LFS strain FH1
(R248W/wt). The percentage reduction of BrdU-labelled cells
occurring as a result of prior exposure to 0.5 and 4 Gy radiation are
listed for all strains tested in Table 1. Multiple repeats were
performed on two normal strains (156MA and 176MA), otherwise
single determinations were performed on most strains.
Permanent arrest
Table 1 also shows the radiation-induced reduction of labelled
cells due to permanent arrest in the G1 phase. The data shown are a
combination of those previously reported (Williams et al, 1997)
and new data acquired under the same conditions in this study.
Statistical analysis of G1 arrest data
Comparison of transient and permanent arrest data obtained for all
strains after 4 Gy showed a significant correlation (Spearman’s
correlation coefficient = 0.768, significant at the 0.01 level).
However, the significance was principally due to the strong corre-
lation correlation (Spearman’s correlation coefficient = 0.879,
1660 JM Boyle et al
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Figure 2 Histograms of inhibition of S phase under conditions of transient arrest after 0.5 Gy (A) and 4 Gy (B) or permanent arrest after 4 Gy (C). Cells are
grouped according to TP53 status. Mean values from Table 1 were binned at 5% intervals and vertical lines indicate 2 standard deviation limits of the mean
values of normal control group 1significant at the 0.001 level) found for the mut/wt strains (Group
2, Table 1). These data were linearly correlated over a wide range
from approximately 20% to 90%. No significant correlations were
found for groups 1 and 4 (normals and non-mutants) whose data
points lay mainly at the top end of the linear response, clustered
between approximately 60–90%.
Variability in the results obtained with the four groups of cells
tested is shown graphically in Figure 2. Mann–Whitney U-tests
were used to compare the group means (Table 2). G1 arrest, both
transient and permanent, was significantly reduced in hetero-
zygous LF cells when compared to both normal and non-mutation
LF cells. In contrast, there was no significant difference between
normal and non-mutant LF cells in either of the assays.
Correlations between G1 arrest and clonogenic
radiosensitivity
The relative clonogenic survivals following exposure to 3 and 
6 Gy of low-dose rate 60Co radiation were 34.4 ± 7.1 and 19.5 ±
10.4 for 193MA, and 45.3 ± 16.5 and 17.9 ± 4.5 for 194MA (mean
percentage survivals ± 1 standard deviation of three independent
experiments). Data for the majority of other strains have been
reported previously (Boyle et al, 1998; Varley et al, 1998).
From a clinical perspective it may be important to identify
abnormal responses for different endpoints in cells from different
individuals. As a general strategy, this can be done by assigning as
abnormal those responses that fall outside limits set by 2 standard
deviations of the mean values of responses obtained from a panel
of normal cells. We used this strategy to assess the effects of TP53
status on G1 arrest and clonogenic radiosensitivity (Table 3). We
defined strains as having compromised G1 arrest if at least two of
the three conditions (transient arrest after 0.5 or 4 Gy and perma-
nent arrest after 4 Gy) showed reduced arrest. We defined as
radioresistant any strain whose clonogenic survival was greater
than the normal limits (41.8% or 14.0%) after exposure to either 
3 Gy or 6 Gy, respectively (Boyle et al, 1998).
The effect of TP53 status on the relationship between G1 arrest
and clonogenic radiosensitivity, is shown in 2 ´ 2 concordance
tables (Table 4), from which it is apparent that there are several
discordant strains in each LF group. Thus both mut/– strains
(161MA-F, 172MA) have reduced G1 arrest but normal radiosensi-
tivity. The dissociation of reduced G1 arrest and radioresistance
was also seen in some heterozygous strains and some strains
without p53 mutations.
Among heterozygous strains, there were two discordant strains,
110MA (E180K/wt) which had normal G1 arrest but was radio-
resistant, and 131MA (R248Q/wt) which had reduced G1 arrest
and normal radiosensitivity. However, two of ten mutation
carrying strains behaved like normal cells in their response to
ionizing radiation, having normal G1 arrest and radiosensitivity,
and six had reduced G1 arrest and were radioresistant, thus
conforming to our original concordance (Table 4).
Of six non-mutation strains tested for both parameters, three
(80MA, 81MA, 126MA) were discordant and had normal G1
responses associated with borderline survival responses (Table 3).
The three concordant strains, 146MA, 154MA and 79MA, had
normal G1 and survival responses. Within family 81, all three strains
tested had normal G1 response, but 80MA and 81MA were slightly
more resistant than 79MA and were differently categorized.
DISCUSSION
Equivalence of G1 methodologies
The two methods that we used to determine radiation-induced G1
arrest in human fibroblast cells showed a highly significant corre-
lation for data from heterozygous LF cells with TP53 mutations
(mut/wt) cells, for which there was a linear response over a wide
range of values after 4 Gy exposure. However, permanent G1 arrest
appears to be more reliable than transient arrest as a means of
discriminating between mut/wt cells and those from families with
no mutation (Table 3). Exposure to doses less than 4 Gy may
improve the correlation between the two methods for normal and
non-mutation groups by inducing less than saturating responses in
these cells.
G1 arrest in Li-Fraumeni family fibroblasts 1661
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Table 2 Analysis of G1 arrest data
Summary of statistics
Transient arrest Permanent arrest
Group 0.5 Gy 4 Gy 4 Gy
an bMean SD n Mean SD n Mean SD
1. Normals 11 60.09 6.88 12 90.67 4.46 12 72.25 10.61
2. LF, wt/mut 12 30.13 19.20 12 67.79 19.78 10 40.74 16.07
3. LF mut/– 2 –12.40 7.49 2 –2.80 1.27 2 16.80 3.82
4. LF, no mutation 15 46.21 22.97 15 77.76 24.31 16 72.79 9.41
P-values of Mann–Whitney U-tests
Groups compared Transient arrest Permanent arrest
0.5 Gy 4 Gy 4 Gy
1 v 2 0.001 0.001 < 0.001
1 v 4 0.59 0.83 0.69
2 v 4 0.001 0.005 < 0.001
aNumber of strains in group; bMean of aggregated means of percentage inhibition of S phase.Effect of TP53 mutations on G1 arrest
Among the mutation-carrying strains, those with mis-sense muta-
tions in the DNA binding region of p53 all showed reduced G1
arrest, although this was marginal for two strains of family 85
(109MA, 110MA) with a mutation in codon 180. Two strains
heterozygous for splice site mutations (178MA, 191MA) gave
responses within the normal range. This was probably not due
simply to reduced gene dosage as a consequence of truncation of
the product of the mutated alleles, because the stop codon muta-
tion in strain 193MA resulted in a reduced response.
Loss of the wt p53 allele drastically reduces G1 arrest
Two strains (161MA-F, 172MA) that had lost the wt p53 allele
(mut/–) but retained mutations in codons 344 and 337, respec-
tively, showed no arrest in the transient assay and greatly reduced
arrest when measured at late times in the permanent assay. This
confirms a similar finding in MDAH087, homozygous for a
mutation in codon 248 (Dulic et al, 1994; Tainsky et al, 1995).
Mutations in codons 344 and 337 affect the oligomerization of p53
(Davison et al, 1998). In vitro L344P prevents dimerization and
binding to the p53 DNA consensus sequence, whereas R337C has
1662 JM Boyle et al
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Table 3 Comparison of G1 arrest and clonogenic radiosensitivity in LF cells compared to normals
Strain (family) aG1 Arrest compared to normal controls
bCell survival TP53 status Transient Permanent
following
0.5 Gy 4 Gy 4 Gy 3 Gy/6 Gy
Group 2 – Mutation carriers
FH1 (266) r r r R/R
R248W/+
163MA (266) r r r R/R
R248W/+
131MA (222) r r r n/n
R248Q/+
138MA (83) r r r R/R
R175H/+
124MA (16) r r r R/R
Y220C/+
109MA (85) r n n n/n
E180K/+
110MA (85) r n n (0.3) R/R
E180K/+
168MA (1502) r r nd nd
R273H/+
178MA (2635) n n n n/n
spl. Don. Exon 3/+
191MA (86) n n nd nd
spl. Acc. Intron 3/-
193MA (2612) r r r n/R
R209stop/+
194MA (64) r r n R/R
P152L/+
Group 3 – Mut/- strains
161MA-F (7379) no arrest no arrest r n/n
L344P/-
172MA no arrest no arrest r n/n
R337/-
Group 4 – Non-mutation families
140MA (22) n r n nd
146MA (80) n (1.6) r n n/n
147MA (80) n n n nd
148MA (80) n n n nd
154MA (80) n n n n/n
79MA (81) n n n n/n
80MA (81) n n n R/n
81MA (81) n (1.4) n n R/n
115MA (82) nd nd n nd
126MA (88) n n n n/R
130MA (88) r r n nd
121MA (119) n (0.6) r n nd
122MA (119) n (1.2) r n nd
127MA (338) n n n nd
128MA (348) n n n nd
107MA (353) r (1.0) n n nd
an, within normal range; r, reduced response, values in parenthesis show the percentage by which marginal cases (within 2% of the lower limit of the normal
range) fall within the given class. bn, within normal range; R, resistant; nd, not determined.a lowered thermal stability such that tetramer formation and
hetero-oligomerization with wt p53 are greatly impaired at
physiological temperatures. Since tetramerization is required for
transactivation of p53 target genes, the reduced G1 arrest seen in
161MA-F and 172MA is consistent with a failure to induce
p21WAF1/CIP1.
G1 arrest is not defective in LF families without TP53
mutations
A major observation of this study was the finding that strains from
all nine families without TP53 mutations (Group 4, Table 3)
showed normal checkpoint responses in at least two, and usually
all, of the three conditions assayed. Direct sequencing of DNA
from normal tissue from donors of these cells had failed to detect
any TP53 mutations (Varley et al, 1997) but it was possible that the
fibroblast cultures derived from these donors might have acquired
mutations in vitro, as had been observed previously (Mirzayans et
al, 1995). To check this possibility we tested cells at passage
numbers comparable to those used in the G1 arrest experiments
using the FASAY (Table 1) which permits detection of expressed
wt and mis-sense mutant p53 alleles (Flaman et al, 1995; Lomax 
et al, 1997). As expected, germline mis-sense mutations yielded
about 50% mutant colonies in the yeast functional assay, whereas
the splice site mutation in 178MA yielded 3% mutant colonies,
which was within the background frequency of ≤ 5% obtained
with wild-type normal cells. Most of the strains from families
without TP53 mutations gave mutant colonies at frequencies
within, or close to, the normal range. However, 80MA and 128MA
gave increased numbers of mutant colonies with some cDNA
preparations but not others, the reason for which is unknown. The
increased number of mutant colonies did not appear to be associ-
ated with reduced G1 arrest since both strains showed normal G1
arrest.
G1 arrest is not a consistent predictor of clonogenic
radiation resistance in LF fibroblasts
In a previous study (Williams et al, 1997) we demonstrated an
inverse correlation between the extent of G1 arrest and radiosensi-
tivity measured after exposure to ionizing radiation given at either
high- or low-dose rates. Because exposure to low-dose rate radia-
tion provides greater discrimination of sensitive and resistant cell
populations in the clonogenic assay, we used this method to
expand the number of strains studied. Our original results
contrasted cells from normal individuals which had, by definition,
normal G1 arrest and radiosensitivity, with Li-Fraumeni cells
mainly from mutation carriers, which had reduced G1 arrest and
were radioresistant. However, in strains that had lost the wild-type
allele (172MA, R337C/- and 161MA-F, L344P/-) there was
reduced G1 arrest but normal radiosensitivity, clearly showing that
the two events are dissociated in the absence of intact p53 (Table
3). The lack of G1 arrest in p53 mut/– strains mimics that of AT
homozygotes (Nagasawa et al, 1985), which are deficient in p53
stabilization following irradiation (Kastan et al, 1992). A similar
effect is seen in embryo (Westphal et al, 1997) and adult skin (JMB
and MJG, unpublished observations) fibroblasts from ATM and
p53 knockout mice. However, AT homozygotes are more sensitive
to ionizing radiation whereas p53 mut/– cells have normal
radiosensitivity (Boyle et al, 1998).
A caveat affecting the interpretation of the results is that our
ability to make a proper classification is critically dependent on the
number of strains used to define normal limits for each of the para-
meters studied, because the group mean will be less strongly influ-
enced by outliers as the sample size increases. The present sample
size (n = 12) is a compromise that allowed a reasonable accuracy
with the available material and manpower resources. Nevertheless,
these observations do appear to emphasize an apparent variability
in phenotypes among Li-Fraumeni cell strains which may be
controlled in part by the site of TP53 mutation and by the genetic
background in which it is expressed. Where a mutation produces a
strong effect (e.g. R248Q in family 266, Table 3; R175H in family
86, Boyle et al, 1998) cells from different members of the family
have similar phenotypes that are sufficiently different from wild-
type to place them in different categories. However, where a muta-
tion has a weaker effect, the phenotypes may be close to wild-type
and small differences in genetic background may place different
individuals into different categories. This is illustrated by family
85 (E180K) where strains 109MA and 110MA both showed
normal G1 arrest, but 110MA was slightly more resistant than
109MA and appeared discordant in comparison.
Cellular phenotypes and p53 involvement in 
non-mutation families
The nine families without TP53 mutations included both classical
LFS (five families) and LFL (four families) patterns of disease.
Within these families the most likely individuals to be carrying a
genetic predisposition towards cancer are those affected by cancer.
The majority of strains (12 of 16) used were from affected individ-
uals, so it is highly probable that we are mainly looking at strains
carrying genetic predisposition towards cancer. Our results
provide no clear evidence to suggest that defective p53 expression
is the cause of cancer predisposition in these families.
Recently, a number of genes have been identified that have
homology with p53, e.g. p73, p53CP and KET (Bian and Sun,
1997; Jost et al, 1997; Kaghad et al, 1997; Schmale and
Bamberger, 1997). Superficially, p73 is an attractive candidate
since, like p53, it is a sequence-specific transactivator that prob-
ably requires oligomerization, and overexpression of p73 induces
p21 and blocks cell proliferation (Kaghad et al, 1997). But, unlike
p53, p73 is neither stabilized nor activated by DNA damage
although in other ways it fulfills many of the functions of p53
(Oren, 1997). Expression of p73 and KET appear largely restricted
to neurological and epithelial tissues, respectively. Thus, at
present, there may be a possibility that cancer predisposition in
p53 non-mutation families could result from mutations in these
genes, or in other homologues still to be discovered, in which case
G1 arrest in Li-Fraumeni family fibroblasts 1663
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Table 4 Concordance between G1 arrest and clonogenic radiosensitivity
Group Number G1 arrest Radiation survival
of strains
Normal Resistant
LF mut/wt 10 Normal 2 1
Reduced 1 6
LF mut/- 2 Normal 0 0
Reduced 2 0
LF non-mutation 6 Normal 3 3
Reduced 0 0cells from these families might be expected to show normal G1
arrest due to an intact p53 response to DNA damage, such as we
have observed in these families.
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